
    
      The study includes three age groups:

      Group 1: healthy adults (18-45 years) Group 2: young children (aged 1-5 years) Group 3:
      infants (aged 5- <12 months of age) Each group will receive 3 vaccine doses which will be
      4-weeks apart.

      The trial is funded by The European & Developing Countries Clinical Trials Partnership
      (EDCTP), European Union
    
  